Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents
5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
Stephen G. Ellis, Gregg W. Stone, David A. Cox, James Hermiller, Charles O'Shaughnessy, Tift Mann, Mark Turco, Ronald Caputo, Patrick J. Bergin, Thomas S. Bowman, Donald S. Baim and TAXUS IV Investigators
Revascularization and Safety in the Diabetic Subset
Rates of (A) all death; (B) MI; (C) ARC ST definite/probable; and (D) TLR through 5 years in 315 patients with medically treated diabetes and 979 patients without medically treated diabetes (DM). Abbreviations as in Figures 1 and 3.